Wnt Signaling Pathway Inhibitors - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Overview

4.1.1 Wnt Signaling Pathway Inhibitors Therapeutics for Cardiovascular Disorders

4.1.2 Research Study on Serum Concentration of Wnt2 in Patients with Acute Coronary Syndrome

4.2 Key Drivers

4.2.1 Maximum Drugs Developed as Small Molecule

4.2.2 Increasing Prevalence of Cancer and Metabolic Diseases

4.2.3 Multiple Therapeutic Areas

4.3 Key Barriers

4.3.1 Complications Associated with Metabolic Diseases and Cancer

4.3.2 High Cost of Disease Management

4.4 Wnt Signaling Pathway Inhibitors Therapeutics Pipeline Analysis

4.4.1 Pipeline Analysis by Phase

4.4.2 Pipeline Analysis by Molecule Type

4.4.3 Pipeline Analysis by Route of Administration

4.4.4 Pipeline Analysis by Company

Chapter 5. Wnt Signaling Pathway Inhibitors Therapeutics Pipeline Analysis by Phase (2018)

5.1 Phase III

5.1.1 SM04690

5.1.1.1 Pre-Clinical results

5.1.1.1.1 Study 1

5.1.1.1.2 Study 2

5.1.1.1.3 Study 3

5.1.1.2 Clinical trial

5.1.1.3 Clinical trial results

5.1.1.4 Technology

5.1.1.5 Financing

5.2 Phase II

5.2.1 CF102

5.2.1.1 Pre-Clinical studies

5.2.1.2 Clinical trial

5.2.1.3 Clinical trial results

5.2.1.4 Strategic development

5.2.1.5 Technology

5.2.1.6 Patent

5.2.1.7 Designation

5.2.2 XXXX

5.2.2.1 Pre-Clinical study

5.2.2.2 Clinical trial

5.2.2.3 Clinical trial results

5.2.2.4 Patents

5.2.3 XXXX

5.2.3.1 Clinical trial

5.2.3.2 Clinical trial results

5.2.3.3 Strategic development

5.2.3.4 Technology

5.2.4 XXXX

5.2.4.1 Pre-Clinical results

5.2.4.2 Clinical trial

5.2.4.3 Clinical trial results

5.2.4.4 Strategic development

5.2.5 XXXX

5.2.5.1 Pre-Clinical study

5.2.5.2 Clinical trial

5.2.5.3 Clinical trial Results

5.2.5.4 Strategic development

5.2.6 XXXX

5.2.6.1 Pre-Clinical study

5.2.6.2 Clinical trial

5.2.6.3 Clinical trial results

5.3 Phase I

5.3.1 CWP291

5.3.1.1 Pre-Clinical study

5.3.1.2 Clinical trial

5.3.1.3 Clinical trial results

5.3.1.4 Strategic Development

5.3.1.5 Technology

5.3.2 XXXX

5.3.2.1 Pre-Clinical study

5.3.2.1.1 Study 1

5.3.2.1.2 Study 2

5.3.2.2 Clinical trials

5.3.2.3 Grant

5.3.2.4 Patent

5.4 Investigational New Drug Application (IND)

5.4.1 SST215

5.4.2 XXXX

5.4.3 XXXX

5.4.3.1 Pre-Clinical study

5.4.3.2 Strategic development

5.4.4 XXXX

5.4.4.1 Pre-Clinical study

5.5 Pre-Clinical

5.5.1 Box-5

5.5.1.1 Patent

5.5.2 XXXX

5.5.2.1 Strategic development

5.5.3 XXXX

5.5.3.1 Strategic development

5.5.3.2 Technology

5.5.4 XXXX

5.5.4.1 Pre-Clinical study

5.5.4.2 Strategic development

5.6 Discovery

5.6.1 SL075

5.6.2 XXXX

5.6.3 XXXX

5.6.3.1 Patent

5.6.3.2 Technology

5.6.4 XXXX

5.6.4.1 Strategic development

5.6.5 XXXX

5.6.6 XXXX

5.6.6.1 Strategic development

5.6.6.2 Technology

5.7 Unknown Phase

5.7.1 Small Molecule Inhibitors of the Wnt Pathway

5.7.1.1 Pre-Clinical study

5.7.1.2 Patent

5.8 Inactive Drugs

Chapter 6. Clinical Trials Review

6.1 Clinical Trials by Region

6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking

7.2 SWOT Analysis

7.2.1 Strengths

7.2.2 Weakness

7.2.3 Opportunities

7.2.4 Threats

7.3 Attribute Analysis

Chapter 8. Company Profiles

8.1 Novartis AG

8.1.1 Business Overview

8.1.2 Product and Service Offerings

8.2 Eisai Co. Ltd.

8.2.1 Business Overview

8.2.2 Product and Service Offerings

8.3 XXXX

8.3.1 Business Overview

8.3.2 Product and Service Offerings

8.4 XXXX

8.4.1 Business Overview

8.4.2 Product and Service Offerings

8.5 Samumed LLC

8.5.1 Business Overview

8.5.2 Product and Service Offerings

8.6 XXXX

8.6.1 Business Overview

8.6.2 Product and Service Offerings

8.7 XXXX

8.7.1 Business Overview

8.7.2 Product and Service Offerings

8.8 XXXX

8.8.1 Business Overview

8.8.2 Product and Service Offerings

8.9 XXXX

8.9.1 Business Overview

8.9.2 Product and Service Offerings

8.10 Can-Fite BioPharma Ltd.

8.10.1 Business Overview

8.10.2 Product and Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.2 Sources and References

9.3 Related Reports

List of Tables

TABLE 1 PIPELINE ANALYSIS OF WNT SIGNALING PATHWAY INHIBITORS THERAPEUTICS, BY COMPANY (2018)

TABLE 2 EC50 VALUE OF SM04690

TABLE 3 DESCRIPTION OF SM04690

TABLE 4 CLINICAL TRIALS OF SM04690

TABLE 5 DESCRIPTION OF CF102

TABLE 6 CLINICAL TRIALS OF CF102

TABLE 7 DESCRIPTION OF XXXX

TABLE 8 CLINICAL TRIALS OF XXXX

TABLE 9 LIST OF PATENTS OF XXXX

TABLE 10 DESCRIPTION OF XXXX

TABLE 11 CLINICAL TRIALS OF XXXX

TABLE 12 DESCRIPTION OF XXXX

TABLE 13 CLINICAL TRIALS OF XXXX

TABLE 14 DESCRIPTION OF XXXX

TABLE 15 CLINICAL TRIALS OF XXXX

TABLE 16 DESCRIPTION OF XXXX

TABLE 17 CLINICAL TRIALS OF XXXX

TABLE 18 DESCRIPTION OF CWP291

TABLE 19 CLINICAL TRIALS OF CWP291

TABLE 20 DESCRIPTION OF XXXX

TABLE 21 CLINICAL TRIALS OF XXXX

TABLE 22 DESCRIPTION OF SST215

TABLE 23 DESCRIPTION OF XXXX

TABLE 24 DESCRIPTION OF XXXX

TABLE 25 DESCRIPTION OF XXXX

TABLE 26 DESCRIPTION OF BOX-5

TABLE 27 DESCRIPTION OF XXXX

TABLE 28 DESCRIPTION OF XXXX

TABLE 29 DESCRIPTION OF XXXX

TABLE 30 DESCRIPTION OF SL075

TABLE 31 DESCRIPTION OF XXXX

TABLE 32 DESCRIPTION OF XXXX

TABLE 33 DESCRIPTION OF XXXX

TABLE 34 DESCRIPTION OF XXXX

TABLE 35 DESCRIPTION OF XXXX

TABLE 36 DESCRIPTION OF SMALL MOLECULE INHIBITORS OF THE WNT PATHWAY

TABLE 37 SUMMARY OF INACTIVE DRUG CANDIDATES AS WNT INHIBITOR

TABLE 38 QUALITATIVE ANLAYSIS OF PHASE II DRUGS

TABLE 39 NOVARTIS AG – AT A GLANCE

TABLE 40 EISAI CO. LTD. – AT A GLANCE

TABLE 41 XXXX – AT A GLANCE

TABLE 42 XXXX – AT A GLANCE

TABLE 43 SAMUMED LLC – AT A GLANCE

TABLE 44 XXXX – AT A GLANCE

TABLE 45 XXXX – AT A GLANCE

TABLE 46 XXXX – AT A GLANCE

TABLE 47 XXXX – AT A GLANCE

TABLE 48 CAN-FITE BIOPHARMA LTD. – AT A GLANCE

List of Figures

FIG 1 RESEARCH METHODOLOGY

FIG 2 SPLIT OF PRIMARY AND SECONDARY RESEARCH

FIG 3 BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT

FIG 4 BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE

FIG 5 CANONICAL WNT SIGNALING PATHWAY

FIG 6 NON-CANONICAL WNT SIGNALING PATHWAY

FIG 7 WNT PATHWAY INHIBITOR THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2018)

FIG 8 WNT SIGNALING PATHWAY INHIBITORS THERAPEUTICS PIPELINE SPLIT, BY MOLECULE TYPE (2018)

FIG 9 WNT SIGNALING PATHWAY INHIBITORS THERAPEUTICS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2018)

FIG 10 BREAKDOWN OF CLINICAL TRIALS, BY REGION

FIG 11 BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

FIG 12 KEY PLAYERS BENCHMARKING

FIG 13 SWOT ANALYSIS